Absci Corporation, a clinical-stage biopharmaceutical company, has announced the commencement of its first clinical trial for ABS-101, an AI-designed biologic aimed at treating inflammatory bowel disease $(IBD)$. The Phase 1 trial is currently underway with the first healthy volunteers dosed in a randomized, placebo-controlled study. ABS-101, engineered using Absci's generative AI platform, boasts superior potency and reduced immunogenicity, offering potential improvements in efficacy and patient convenience with quarterly dosing. Interim data from this trial is anticipated in the second half of 2025. Additionally, Absci is advancing ABS-201, an AI-designed anti-prolactin receptor antibody for treating androgenetic alopecia, with preclinical data showing promising results. The Phase 1 trials for ABS-201 are expected to commence in early 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。